Imeik Technology Development Co - Asset Resilience Ratio
Imeik Technology Development Co (300896) has an Asset Resilience Ratio of 26.02% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Imeik Technology Development Co to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Imeik Technology Development Co's Asset Resilience Ratio has changed over time. See 300896 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Imeik Technology Development Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Imeik Technology Development Co.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.38 Billion | 26.02% |
| Total Liquid Assets | CN¥2.38 Billion | 26.02% |
Asset Resilience Insights
- Very High Liquidity: Imeik Technology Development Co maintains exceptional liquid asset reserves at 26.02% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Imeik Technology Development Co Industry Peers by Asset Resilience Ratio
Compare Imeik Technology Development Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.87% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
Tarsons Products Limited
NSE:TARSONS |
Medical Instruments & Supplies | 0.47% |
|
SciVision Biotech Inc
TW:1786 |
Medical Instruments & Supplies | 7.81% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
Annual Asset Resilience Ratio for Imeik Technology Development Co (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Imeik Technology Development Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.18% | CN¥2.15 Billion ≈ $315.23 Million |
CN¥8.91 Billion ≈ $1.30 Billion |
-10.32pp |
| 2024-12-31 | 34.50% | CN¥2.88 Billion ≈ $421.12 Million |
CN¥8.34 Billion ≈ $1.22 Billion |
+16.93pp |
| 2023-12-31 | 17.57% | CN¥1.20 Billion ≈ $176.20 Million |
CN¥6.85 Billion ≈ $1.00 Billion |
+6.33pp |
| 2022-12-31 | 11.24% | CN¥703.69 Million ≈ $102.97 Million |
CN¥6.26 Billion ≈ $915.82 Million |
+4.22pp |
| 2021-12-31 | 7.03% | CN¥370.51 Million ≈ $54.22 Million |
CN¥5.27 Billion ≈ $771.47 Million |
-10.99pp |
| 2020-12-31 | 18.01% | CN¥841.57 Million ≈ $123.15 Million |
CN¥4.67 Billion ≈ $683.61 Million |
+11.10pp |
| 2016-12-31 | 6.92% | CN¥21.71 Million ≈ $3.18 Million |
CN¥313.86 Million ≈ $45.93 Million |
-5.34pp |
| 2015-12-31 | 12.25% | CN¥21.16 Million ≈ $3.10 Million |
CN¥172.64 Million ≈ $25.26 Million |
-7.15pp |
| 2014-12-31 | 19.41% | CN¥20.43 Million ≈ $2.99 Million |
CN¥105.29 Million ≈ $15.41 Million |
-- |
About Imeik Technology Development Co
Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate compos… Read more